# Phase 1/2 breast cancer trials recruiting: 165 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 165 trials in phase 1/2 for breast cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 breast cancer trials: 165 rows for $8.25, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/breast-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 165
- Recruiting or not yet: 165
- Read on: November 19, 2026

## Trials

The 25 newest of 165, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 27, 2026 | NCT07899632 | A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors | Medsyn Biopharma, LLC | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899632) |
| October 6, 2026 | NCT07861932 | A Phase 1/2a Study of K-1728 in Advanced Solid Tumors | KymaThera, Inc. | Phase 1/2 | Recruiting | Breast Neoplasms, Solid Tumors, PIK3CA Gene Mutation | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861932) |
| September 10, 2026 | NCT07811232 | A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers | Advenchen Pharmaceuticals, LLC. | Phase 1/2 | Not yet recruiting | Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811232) |
| August 28, 2026 | NCT07793656 | mRNA Therapy to Restore Lymphatic Flow in Secondary Lymphedema | University Hospital, Toulouse | Phase 1/2 | Not yet recruiting | Secondary Lymphedema | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07793656) |
| August 19, 2026 | NCT07774624 | Study of SKB103 in HER2-negative Breast Cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Breast Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07774624) |
| August 17, 2026 | NCT07767474 | A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors | Antares Therapeutics, Inc | Phase 1/2 | Recruiting | Advanced Solid Tumors | 343 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07767474) |
| August 13, 2026 | NCT07762703 | Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS\<10), gBRCA Negative, Triple... | BreakBio Corp | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07762703) |
| August 7, 2026 | NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | LG Chem | Phase 1/2 | Not yet recruiting | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast... | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752875) |
| August 6, 2026 | NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | Arvinas Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 499 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749586) |
| August 4, 2026 | NCT07743723 | A Study of IOV-5001 in Adults With Advanced Solid Tumors | Iovance Biotherapeutics, Inc. | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Head and... | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743723) |
| July 31, 2026 | NCT07739511 | Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | HER2 + Breast Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739511) |
| July 31, 2026 | NCT07739485 | Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Triple -Negative Breast Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739485) |
| July 31, 2026 | NCT07738341 | GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ) | Eddingpharm (Zhuhai) Co., Ltd. | Phase 1/2 | Recruiting | Breast Cancer (Locally Advanced or Metastatic) | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07738341) |
| July 28, 2026 | NCT07730125 | Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies | CoRegen, Inc. | Phase 1/2 | Not yet recruiting | HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Prostate Cancer | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730125) |
| July 16, 2026 | NCT07708194 | Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure | Tianjin Medical University Cancer Institute and Hospital | Phase 1/2 | Recruiting | Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Metastatic Breast Cancer | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07708194) |
| July 15, 2026 | NCT07705074 | FAPI PET Imaging - An Exploratory Study | Sponsor not shown (see the record) | Phase 1/2 | Not yet recruiting | Thyroid Pathology, Head and Neck Cancer (H&N), Sinonasal Tract Tumor, Sarcoidosis, Thyroid Cancer, Breast Cancer... | 770 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705074) |
| July 14, 2026 | NCT07701941 | A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low... | Daiichi Sankyo | Phase 1/2 | Recruiting | Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07701941) |
| July 13, 2026 | NCT07698106 | Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC | University Health Network, Toronto | Phase 1/2 | Recruiting | Triple-Negative Breast Cancer (TNBC) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07698106) |
| July 13, 2026 | NCT07697443 | Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1/2 | Recruiting | Breast Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07697443) |
| July 2, 2026 | NCT07681297 | Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and... | National University Hospital, Singapore | Phase 1/2 | Not yet recruiting | Advanced Solid Tumor Cancer, Triple-Negative Breast Cancer (TNBC), CNS Disease, Breast Cancer | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07681297) |
| May 29, 2026 | NCT07612891 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With... | Shenzhen Ionova Life Sciences Co., Ltd. | Phase 1/2 | Recruiting | Breast Cancer (Locally Advanced or Metastatic), Advanced Solid Cancers, Metastatic (Stage IV) Breast Cancer, Ovarian... | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07612891) |
| May 28, 2026 | NCT07612215 | Elacestrant in Advanced Triple Positive Breast Cancer | NYU Langone Health | Phase 1/2 | Recruiting | ER Positive, HER2 Positive Breast Cancer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07612215) |
| May 19, 2026 | NCT07596212 | BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who... | University of Illinois Chicago | Phase 1/2 | Not yet recruiting | Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder, Hormone Receptor Positive Breast Carcinoma, Breast Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07596212) |
| May 12, 2026 | NCT07581314 | Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) | Telomir Pharmaceuticals, Inc. | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC), Advanced Triple-Negative Breast Cancer, Metastatic Triple-negative Breast Cancer | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07581314) |
| April 30, 2026 | NCT07560124 | A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer | Akeso | Phase 1/2 | Not yet recruiting | Breast Cancer | 286 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07560124) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National University Hospital, Singapore | 4 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 3 |
| Essen Biotech | 3 |
| [Beijing Biotech](https://specstream.ai/data/clinical-trials/company/beijing-biotech) | 3 |
| [Shandong Suncadia Medicine Co., Ltd.](https://specstream.ai/data/clinical-trials/company/shandong-suncadia-medicine-co-ltd) | 2 |
| Forward Pharmaceuticals Co., Ltd. | 2 |
| Cancer Research UK | 2 |
| DualityBio Inc. | 2 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 2 |
| [Jiangsu HengRui Medicine Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hengrui-medicine-co-ltd) | 2 |
| University of Florida | 2 |
| Institut Paoli-Calmettes | 2 |
| [Chia Tai Tianqing Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-co-ltd) | 2 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2 |
| Hadassah Medical Organization | 2 |
| Fudan University | 2 |
| Tianjin Medical University Cancer Institute and Hospital | 2 |
| [Gilead Sciences](https://specstream.ai/data/clinical-trials/company/gilead-sciences) | 2 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 2 |
| Onchilles Pharma Inc | 1 |
| RayzeBio, Inc. | 1 |
| NYU Langone Health | 1 |
| Hummingbird Bioscience | 1 |
| Volastra Therapeutics, Inc. | 1 |
| Shenzhen Ionova Life Sciences Co., Ltd. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 81 |
| China | 47 |
| Australia | 25 |
| Spain | 22 |
| South Korea | 19 |
| United Kingdom | 18 |
| France | 18 |
| Canada | 15 |
| Japan | 15 |
| Italy | 13 |
| Germany | 11 |
| Taiwan | 8 |
| Singapore | 7 |
| Israel | 7 |
| Belgium | 7 |
| Netherlands | 5 |
| Ireland | 3 |
| Egypt | 2 |
| Puerto Rico | 2 |
| Poland | 2 |
| Turkey (Türkiye) | 2 |
| Portugal | 2 |
| Czechia | 2 |
| Denmark | 2 |
| Russia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Medical service organizations in the United States](https://specstream.ai/data/businesses/medical-service-organizations/united-states)
- [Home insurance agencies in the United States](https://specstream.ai/data/businesses/home-insurance-agencies/united-states)
- [Electricians in the United States](https://specstream.ai/data/businesses/electricians/united-states)
- [Cancer treatment centers in the United States](https://specstream.ai/data/businesses/cancer-treatment-centers/united-states)
- [Appraisers in the United States](https://specstream.ai/data/businesses/appraisers/united-states)
- [Tenant and eviction law firms in the United States](https://specstream.ai/data/businesses/tenant-and-eviction-law-firms/united-states)
